A recent analysis of Luxturna (voretigene neparvovec-rzyl) for the treatment of a rare retinal dystrophy (RPE65-mediated blindness), for example, looked at FDA review documents written prior to the drug’s December 2017 approval. Here, RPE65 is linked to inherited retinal dystrophy.